Hungary

Hungary

Hepatitis B

Download HBV data

Prevalence of chronic HBV (HBsAg+)

National
Download
Value (%) Year Type Source
0.68 (0.63 - 0.74) 2019 Modelled IHME
0.69 (0.64 - 0.74) 2018 Modelled IHME
0.69 (0.64 - 0.75) 2017 Modelled IHME
0.69 (0.64 - 0.75) 2016 Modelled IHME
0.69 (0.64 - 0.75) 2015 Modelled IHME
0.69 (0.64 - 0.75) 2014 Modelled IHME
0.69 (0.64 - 0.75) 2013 Modelled IHME
0.7 (0.64 - 0.76) 2012 Modelled IHME
0.7 (0.64 - 0.76) 2011 Modelled IHME
0.7 (0.65 - 0.77) 2010 Modelled IHME
0.7 (0.65 - 0.77) 2009 Modelled IHME
0.7 (0.65 - 0.77) 2008 Modelled IHME
0.71 (0.65 - 0.77) 2007 Modelled IHME
0.71 (0.65 - 0.77) 2006 Modelled IHME
0.71 (0.65 - 0.77) 2005 Modelled IHME
0.71 (0.65 - 0.77) 2004 Modelled IHME
0.71 (0.65 - 0.78) 2003 Modelled IHME
0.72 (0.65 - 0.78) 2002 Modelled IHME
0.72 (0.65 - 0.79) 2001 Modelled IHME
0.72 (0.65 - 0.79) 2000 Modelled IHME
0.73 (0.65 - 0.79) 1999 Modelled IHME
0.73 (0.66 - 0.79) 1998 Modelled IHME
0.73 (0.67 - 0.79) 1997 Modelled IHME
0.74 (0.67 - 0.79) 1996 Modelled IHME
0.74 (0.67 - 0.80) 1995 Modelled IHME
0.74 (0.67 - 0.80) 1994 Modelled IHME
0.74 (0.68 - 0.80) 1993 Modelled IHME
0.74 (0.67 - 0.81) 1992 Modelled IHME
0.74 (0.67 - 0.81) 1991 Modelled IHME
0.74 (0.66 - 0.82) 1990 Modelled IHME
0.4 (0.10 - 1) 2009 Survey/reported Treso B, 2012
0.45 (0.19 - 0.96) 2015 Modelled WHO
Showing out of
Show more
Children under-5 years
Download
Value (%) Year Type Source
0.22 (0.16 - 0.30) 2019 Modelled IHME
0.22 (0.17 - 0.29) 2018 Modelled IHME
0.22 (0.17 - 0.29) 2017 Modelled IHME
0.22 (0.16 - 0.29) 2016 Modelled IHME
0.22 (0.16 - 0.30) 2015 Modelled IHME
0.22 (0.16 - 0.30) 2014 Modelled IHME
0.22 (0.16 - 0.30) 2013 Modelled IHME
0.23 (0.16 - 0.30) 2012 Modelled IHME
0.23 (0.16 - 0.30) 2011 Modelled IHME
0.23 (0.17 - 0.31) 2010 Modelled IHME
0.23 (0.17 - 0.30) 2009 Modelled IHME
0.23 (0.17 - 0.30) 2008 Modelled IHME
0.23 (0.17 - 0.30) 2007 Modelled IHME
0.23 (0.17 - 0.31) 2006 Modelled IHME
0.23 (0.17 - 0.31) 2005 Modelled IHME
0.23 (0.17 - 0.31) 2004 Modelled IHME
0.24 (0.17 - 0.31) 2003 Modelled IHME
0.24 (0.18 - 0.31) 2002 Modelled IHME
0.24 (0.18 - 0.31) 2001 Modelled IHME
0.24 (0.18 - 0.32) 2000 Modelled IHME
0.25 (0.19 - 0.32) 1999 Modelled IHME
0.25 (0.19 - 0.33) 1998 Modelled IHME
0.26 (0.19 - 0.33) 1997 Modelled IHME
0.27 (0.20 - 0.34) 1996 Modelled IHME
0.27 (0.20 - 0.35) 1995 Modelled IHME
0.27 (0.20 - 0.35) 1994 Modelled IHME
0.27 (0.20 - 0.35) 1993 Modelled IHME
0.27 (0.20 - 0.35) 1992 Modelled IHME
0.27 (0.20 - 0.35) 1991 Modelled IHME
0.27 (0.19 - 0.35) 1990 Modelled IHME
0.44 (0.18 - 0.97) 2015 Modelled WHO
Showing out of
Show more
Prisoners
Download
Value (%) Year Type Source
1.5 (1.20 - 1.80) 2009 Survey/reported Treso B et al, 2012

Percent of liver cancer deaths attributable to HBV

National
Download
Value (%) Year Type Source
20 (14 - 28) 2019 Modelled IHME
20 (15 - 28) 2018 Modelled IHME
21 (15 - 29) 2017 Modelled IHME
21 (15 - 29) 2016 Modelled IHME
21 (15 - 29) 2015 Modelled IHME
21 (15 - 29) 2014 Modelled IHME
21 (15 - 29) 2013 Modelled IHME
21 (15 - 29) 2012 Modelled IHME
21 (15 - 29) 2011 Modelled IHME
22 (15 - 29) 2010 Modelled IHME
22 (16 - 29) 2009 Modelled IHME
22 (16 - 29) 2008 Modelled IHME
22 (16 - 30) 2007 Modelled IHME
22 (16 - 30) 2006 Modelled IHME
22 (16 - 30) 2005 Modelled IHME
22 (16 - 30) 2004 Modelled IHME
22 (16 - 30) 2003 Modelled IHME
22 (16 - 30) 2002 Modelled IHME
22 (16 - 29) 2001 Modelled IHME
22 (16 - 29) 2000 Modelled IHME
22 (16 - 29) 1999 Modelled IHME
22 (16 - 30) 1998 Modelled IHME
22 (16 - 30) 1997 Modelled IHME
22 (15 - 30) 1996 Modelled IHME
22 (15 - 30) 1995 Modelled IHME
22 (15 - 30) 1994 Modelled IHME
22 (15 - 30) 1993 Modelled IHME
21 (15 - 30) 1992 Modelled IHME
21 (15 - 29) 1991 Modelled IHME
21 (15 - 29) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
21 2017 Survey/reported EMCDDA, 2019
48 (32 - 91) 2016 Survey/reported Hungary National Institute for Health Development, 2016
Showing out of
Show more
Technical notes
HBV National Action Plan
HBV elimination goal
HepB birth dose policy
No
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
No
OST in at least one prison
No
% of substance use disorder facilities offering hepatitis testing
Many (31-60%)
% of substance use disorder facilities offering hepatitis treatment
Few (1-10%)

Hepatitis C

Download HCV data

Prevalence of chronic HCV (RNA+/cAg)

National
Download
Value (%) Year Type Source
1.21 (0.98 - 1.49) 2019 Modelled IHME
1.2 (0.98 - 1.47) 2018 Modelled IHME
1.2 (0.97 - 1.47) 2017 Modelled IHME
1.21 (0.99 - 1.47) 2016 Modelled IHME
1.22 (1 - 1.49) 2015 Modelled IHME
1.23 (1.01 - 1.50) 2014 Modelled IHME
1.25 (1.03 - 1.52) 2013 Modelled IHME
1.27 (1.04 - 1.54) 2012 Modelled IHME
1.28 (1.05 - 1.56) 2011 Modelled IHME
1.3 (1.06 - 1.58) 2010 Modelled IHME
1.31 (1.07 - 1.61) 2009 Modelled IHME
1.33 (1.08 - 1.62) 2008 Modelled IHME
1.34 (1.09 - 1.64) 2007 Modelled IHME
1.36 (1.10 - 1.66) 2006 Modelled IHME
1.38 (1.11 - 1.68) 2005 Modelled IHME
1.4 (1.13 - 1.71) 2004 Modelled IHME
1.43 (1.16 - 1.74) 2003 Modelled IHME
1.46 (1.19 - 1.78) 2002 Modelled IHME
1.49 (1.22 - 1.82) 2001 Modelled IHME
1.52 (1.24 - 1.85) 2000 Modelled IHME
1.54 (1.26 - 1.88) 1999 Modelled IHME
1.55 (1.27 - 1.90) 1998 Modelled IHME
1.57 (1.29 - 1.92) 1997 Modelled IHME
1.59 (1.30 - 1.94) 1996 Modelled IHME
1.6 (1.31 - 1.96) 1995 Modelled IHME
1.61 (1.32 - 1.97) 1994 Modelled IHME
1.63 (1.34 - 1.98) 1993 Modelled IHME
1.64 (1.34 - 1.99) 1992 Modelled IHME
1.65 (1.35 - 1.99) 1991 Modelled IHME
1.66 (1.35 - 2.02) 1990 Modelled IHME
Showing out of
Show more

Prevalence of anti-HCV

National
Download
Value (%) Year Type Source
0.5 (0.20 - 1.10) 2009 Survey/reported Treso B, 2012
0.8 (0.40 - 2.70) 2014 Modelled Gower et al, 2014
0.8 (0.40 - 2.70) 2014 Modelled Gower et al, 2014
Showing out of
Show more
People who inject drugs (PWID)
Download
Value (%) Year Type Source
46.6 (30.40 - 62.80) 2015 Modelled Degenhardt L et al, 2017
24.1 (20.80 - 27.60) 2011 Survey/reported EMCDDA
Showing out of
Show more
Prisoners
Download
Value (%) Year Type Source
4.9 (4.30 - 5.60) 2009 Survey/reported Treso B et al, 2012

Percent of liver cancer deaths attributable to HCV

National
Download
Value (%) Year Type Source
26 (18 - 34) 2019 Modelled IHME
26 (18 - 34) 2018 Modelled IHME
26 (18 - 34) 2017 Modelled IHME
26 (18 - 34) 2016 Modelled IHME
26 (18 - 34) 2015 Modelled IHME
26 (18 - 34) 2014 Modelled IHME
26 (18 - 34) 2013 Modelled IHME
25 (18 - 33) 2012 Modelled IHME
25 (18 - 33) 2011 Modelled IHME
25 (18 - 33) 2010 Modelled IHME
25 (18 - 33) 2009 Modelled IHME
25 (18 - 32) 2008 Modelled IHME
25 (18 - 32) 2007 Modelled IHME
25 (18 - 32) 2006 Modelled IHME
25 (18 - 32) 2005 Modelled IHME
25 (17 - 32) 2004 Modelled IHME
24 (17 - 32) 2003 Modelled IHME
24 (17 - 32) 2002 Modelled IHME
25 (17 - 32) 2001 Modelled IHME
24 (17 - 32) 2000 Modelled IHME
24 (17 - 32) 1999 Modelled IHME
25 (17 - 32) 1998 Modelled IHME
25 (17 - 32) 1997 Modelled IHME
25 (17 - 33) 1996 Modelled IHME
25 (17 - 33) 1995 Modelled IHME
25 (17 - 32) 1994 Modelled IHME
24 (17 - 32) 1993 Modelled IHME
24 (17 - 32) 1992 Modelled IHME
24 (17 - 32) 1991 Modelled IHME
24 (17 - 32) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
300 2017 Survey/reported EMCDDA, 2019
48 (32 - 91) 2016 Survey/reported Hungary National Institute for Health Development, 2016
Showing out of
Show more
Technical notes
HBV National Action Plan
HBV elimination goal
HepB birth dose policy
No
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
No
OST in at least one prison
No
% of substance use disorder facilities offering hepatitis testing
Many (31-60%)
% of substance use disorder facilities offering hepatitis treatment
Few (1-10%)

Overview

HBV elimination goal
HCV elimination goal

Prevalence (national)

Modelled

HBV (HBsAg+)
0.68 (%)
2019
(0.63 - 0.74(%))
IHME
HCV (RNA/cAg+)
1.21 (%)
2019
(0.98 - 1.49(%))
IHME

Survey/surveillance

HBV (HBsAg+)
0.4 (%)
2009
(0.1 - 1(%))
Treso B, 2012
HCV (anti-HCV)
0.5 (%)
2009
(0.2 - 1.1(%))
Treso B, 2012

Hepatitis related deaths (national)

Modelled

HBV
1,115
2019
(830 - 1,477)
IHME

Survey/surveillance

No data available
HBV chart

Modelled

HCV
644
2019
(452 - 900)
IHME

Survey/surveillance

No data available
HCV chart

Prevalence < 5

HBV
0.22 (%)
2019, latest modelled
(0.16 - 0.30(%))
IHME

Prevalence PWID

HCV
24.10 (%)
2011, survey/surveillance
(20.80 - 27.60(%))
EMCDDA

Birth dose vaccination coverage (national)

Survey/surveillance

No data available

No. of syringes/PWID/year

Survey/surveillance

HCV
21
2017
EMCDDA, 2019
Eligible for HBV generic medicines
Eligible for HCV generic medicines